一个高度融合和生物模拟的波醇总合成
1Department of Chemistry and Center for Integrated Protein Science, Ludwig-Maximilians-Universität München , Butenandtstrasse 5-13, 81377 München, Germany.
Journal of the American Chemical Society
|October 17, 2015
概括
研究人员报告了一种非同寻常的多基基醇的有效总合成. 关键步骤包括醇反应和生物模拟循环级联,产生波醇和无水波醇.
科学领域:
- 有机化学
- 自然产品合成
- 多基化工学
背景情况:
- 波醇是一种具有复杂结构的异常多基.
- 由于其立体化学复杂性,聚基酸的合成存在重大挑战.
研究的目的:
- 开发一种高效的天然产品合成.
- 探索构建多基核的仿生策略.
主要方法:
- 使用三种醇反应来构建线性碳骨.
- 使用由氧化启动的生物模拟双循环级联.
- 合成了波醇及其脱水产物无水波醇.
主要成果:
- 一个不寻常的多基化物.
- 合成的特点是构建两个具有挑战性的反反立体.
- 一个仿生级联有效地产生波醇和无水波醇.
结论:
- 报告的合成提供了一个有效的途径,以portentol.
- 该研究讨论了波醇的生物合成以及关键合成步骤与生物合成途径的相关性.
相关概念视频
Biosynthesis of Lipids
870
Microbial membranes exhibit remarkable diversity in lipid composition, reflecting evolutionary adaptations to various environmental conditions. The three domains of life—Bacteria, Archaea, and Eukarya—synthesize membrane lipids through distinct biosynthetic pathways, leading to fundamental structural differences that impact membrane stability, function, and adaptability.Fatty Acid-Based Lipids in Bacteria and EukaryaBacteria and eukaryotes share a common fatty acid biosynthesis...
870
Combined Effects of Drugs: Synergism
7.4K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
7.4K
Pharmaceutical Equivalents
259
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
259
Prodrugs
4.7K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
4.7K
Production of Pharmaceuticals
59
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under...
59
Drug Biotransformation: Overview
4.2K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
4.2K


